Back to results
US 12,584,905 B2Granted
Method for identifying molecular markers of children's skin
AssigneeLaboratoires Expanscience
InventorsPhilippe Msika, Caroline Baudouin
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for identifying biological markers for characterizing children's skin. The method of the invention thus makes it possible to identify molecular markers that are expressed differently in children's skin than in the skin of adults. The present invention therefore enables the skin to be characterized at the molecular level from birth and the changes thereof with age to be tracked.
Claims12
A method for evaluating the tolerance, by children's skin, of a composition comprising mannoheptulose and perseitol comprising the following steps:
- a) measuring the level of expression or the activity of a combination of candidate biological markers in at least one reconstructed skin culture (A), said culture being obtained from a donor under 16 years of age,
- wherein said combination of candidate biological markers of children's skin is the combination of genes, proteins, hormones or enzymes consisting of:
- IGFL3 (IGF-like family member 3);
- GP3X (glutathione peroxidase 3);
- MGST1 (microsomal glutathione S-transferase 1);
- DEFB1 (defensin beta1);
- DEFB4 (defensin beta4);
- CDKN1 (cyclin-dependent kinase inhibitor);
- BARX2 (BARx Homeobox 2);
- SCEL (sciellin);
- CLDN1 (claudin 1);
- IVL (involucrin);
- KRT1 (keratin 1);
- CADM1 (cell adhesion molecule 1);
- FN1 (fibronectin 1);
- NID1 (nidogen 1);
- NOTCH1 (Notch homolog 1, translocation-associated);
- KRT19 (keratin 19);
- ITGB1BP1 (integrin beta1 binding protein);
- ITGA6 (integrin alpha6);
- and
- ITGB4 (integrin beta4);
- b) measuring the level of expression or the activity of said combination of candidate biological markers in at least one control sample (B) of skin cells, wherein the control sample (B) is obtained from an adult,
- c) determining that the combination of candidate markers is a combination of biological markers of children's skin, wherein the level of expression or the activity of step b) is different from the level of expression or the activity of step a), wherein said combination of candidate biological markers is a combination of biological markers of children's skin;
- d) contacting a composition comprising mannoheptulose and perseitol, with the reconstructed skin culture (A);
- e) measuring the level of expression of interleukin 8 (IL8), and measuring the level of expression or the activity of the combination of biological markers of children's skin of step c) in the reconstructed skin culture (A) after step d);
- and
- f) measuring the level of expression of interleukin 8 (IL8), and measuring the level of expression or the activity of the combination of biological markers of children's skin of step c) in a control sample;
- and
- g) determining the tolerance of the composition, by children's skin based on the levels of expression or the activity measured in steps e) and f), and
- h) preparing a cosmetic, pharmaceutical, nutritional and/or nutraceutical formulation for children if, and only if, the composition does not significantly modulate the level of expression of interleukin 8 (IL8) and the composition does not significantly modulate the level of expression or the activity of the combination of markers of children's skin.
28 more elements
A method for evaluating the tolerance, by children's skin, of a composition comprising mannoheptulose and perseitol comprising the following steps:
- a) measuring the level of expression or the activity of a combination of candidate biological markers in at least two reconstructed skin cultures (A) and (A′);
- said culture (A) being obtained from a newborn donor, between 0 and 1 month of age, and said culture (A′) being obtained from an infant donor, between 1 month and 2 years of age, wherein said combination of candidate biological markers of children's skin is the combination of genes, proteins, hormones or enzymes consisting of:
- IGFL3 (IGF-like family member 3);
- GP3X (glutathione peroxidase 3);
- MGST1 (microsomal glutathione S-transferase 1);
- DEFB1 (defensin beta 1);
- DEFB4 (defensin beta4);
- CDKN1 (cyclin-dependent kinase inhibitor);
- BARX2 (BARx Homeobox 2);
- SCEL (sciellin);
- CLDN1 (claudin 1);
- IVL (involucrin);
- KRT1 (keratin 1);
- CADMI (cell adhesion molecule 1);
- FN1 (fibronectin 1);
- NID1 (nidogen 1);
- NOTCHI (Notch homolog 1, translocation-associated);
- KRT19 (keratin 19);
- ITGB1BP1 (integrin betal binding protein);
- ITGA6 (integrin alpha6);
- andITGB4 (integrin beta4);
- b) measuring the level of expression or the activity of said combination of candidate biological markers in at least one control sample (B) of skin cells, wherein the control sample (B) is obtained from an adult,
- c) determining that the combination of candidate markers is a combination of biological markers of children's skin, wherein the level of expression or the activity of step b) is different from the level of expression or the activity of step a), wherein said combination of candidate biological markers is a combination of biological markers of children's skin;
- d) contacting a composition comprising mannoheptulose and perseitol, with the reconstructed skin culture (A) and (A′);
- e) measuring the level of expression of interleukin 8 (IL8), and measuring the level of expression or the activity of the combination of the biological markers of children's skin of step c) in the reconstructed skin culture (A) and (A′) after step d);
- and
- f) measuring the level of expression of interleukin 8 (IL8), and measuring the level of expression or the activity of the combination of the biological markers of children's skin of step c) in a control sample;
- g) determining the tolerance of the composition, by children's skin based on the levels of expression or the activity measured in steps e) and f), and
- h) preparing a cosmetic, pharmaceutical, nutritional and/or nutraceutical formulation for children if, and only if, the composition does not significantly modulate the level of expression of interleukin 8 (IL8) and the composition does not significantly modulate the level of expression or the activity of the combination of markers of children's skin.
26 more elements
Dependencies are inferred from the claim text.